Bioinformatics-Based Analysis: Noncoding RNA-Mediated COL10A1 Is Associated with Poor Prognosis and Immune Cell Infiltration in Pancreatic Cancer
Open Access
- 5 September 2022
- journal article
- research article
- Published by Wiley in Journal of Healthcare Engineering
- Vol. 2022, 1-16
Abstract
Background. Collagen type X alpha 1 (COL10A1) is a structural component of the extracellular matrix that is aberrantly expressed in a variety of cancer tissues. However, its role in pancreatic cancer progression is not well understood. Methods. The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and Gene Expression Profiling Interaction Analysis (GEPIA) data were employed to explore the expression of COL10A1 in normal and tumor tissues and its prognostic value in pancreatic adenocarcinoma. The clinical data of pancreatic cancer in TCGA were used to explore the relationship between COL10A1 and clinical features. Genes coexpressed with COL10A1 were explored using multiple databases and analyzed for functional enrichment. In addition, the lncRNA/miRNA/COL10A1 axis that may be involved in COL10A1 regulation in pancreatic cancer was explored by constructing a competitive endogenous RNA (ceRNA) regulatory axis. Finally, COL10A1 was analyzed for correlation with immune cell infiltration and various immune checkpoint molecules in pancreatic cancer. Results. It was found that the expression of COL10A1 was significantly increased in pancreatic cancer tissues. High expression of COL10A1 was related to the clinicopathological characteristics and the worse prognosis of pancreatic cancer patients. The TUG1/miR-144-3p/COL10A1 axis was identified as the most likely upstream noncoding RNA pathway for COL10A1 in pancreatic cancer. Besides, in pancreatic adenocarcinoma, the expression level of COL10A1 showed a significant positive correlation with tumor immune cell infiltration, biomarkers of immune cells, and expression of immune checkpoint molecules. Conclusion. COL10A1 is an early diagnostic marker, and its high expression correlates with immune infiltration in pancreatic cancer. The TUG1/miR-144-3p/COL10A1 axis was identified as the most likely upstream noncoding RNA pathway for COL10A1 in pancreatic cancer.Keywords
Funding Information
- Department of Finance of Jilin Province (#2020SCZT004)
This publication has 57 references indexed in Scilit:
- Immunotherapy for lung cancerRespirology, 2016
- Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studiesWorld Journal of Gastroenterology, 2016
- Cancer immunotherapy: harnessing the immune system to battle cancerJournal of Clinical Investigation, 2015
- starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein–RNA interaction networks from large-scale CLIP-Seq dataNucleic Acids Research, 2013
- Role of non-classical MHC class I molecules in cancer immunosuppressionOncoImmunology, 2013
- Innate and adaptive immune cells in the tumor microenvironmentNature Immunology, 2013
- COL10A1 Expression is Elevated in Diverse Solid Tumor Types and is Associated with Tumor VasculatureFuture Oncology, 2012
- Pancreatic cancerThe Lancet, 2011
- A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?Cell, 2011
- Type X collagen, a product of hypertrophic chondrocytesBiochemical Journal, 1985